Author
Listed:
- Jiekun Yang
(Massachusetts Institute of Technology
Broad Institute of MIT and Harvard
Rutgers University-New Brunswick
Rutgers University-New Brunswick)
- Cassia Wang
(Massachusetts Institute of Technology)
- Doris Fu
(Massachusetts Institute of Technology)
- Li-Lun Ho
(Massachusetts Institute of Technology
Broad Institute of MIT and Harvard)
- Kyriakitsa Galani
(Massachusetts Institute of Technology
Broad Institute of MIT and Harvard)
- Lee Chen
(Massachusetts Institute of Technology)
- Jose Gonzalez
(Rutgers University-New Brunswick
Rutgers University-New Brunswick)
- Jolene Fu
(Rutgers University-New Brunswick
Rutgers University-New Brunswick)
- Amy Y. Huang
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute
Harvard Medical School)
- Dennie T. Frederick
(Mass General Brigham)
- Liang He
(Massachusetts Institute of Technology
Broad Institute of MIT and Harvard)
- Mukta Asnani
(Rutgers University-New Brunswick
Rutgers University-New Brunswick)
- Rahul Tacke
(Massachusetts Institute of Technology)
- Emily J. Robitschek
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute
Harvard Medical School)
- Sandeep K. Yadav
(University of Texas MD Anderson Cancer Center)
- Wentao Deng
(University of Texas MD Anderson Cancer Center)
- Kelly P. Burke
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute
Harvard Medical School)
- Tatyana Sharova
(Mass General Brigham)
- Ryan J. Sullivan
(Harvard Medical School
Mass General Brigham)
- Sarah Weiss
(Rutgers Cancer Institute)
- Kunal Rai
(University of Texas MD Anderson Cancer Center)
- David Liu
(Broad Institute of MIT and Harvard
Dana-Farber Cancer Institute
Harvard Medical School)
- Genevieve M. Boland
(Broad Institute of MIT and Harvard
Mass General Brigham)
- Manolis Kellis
(Massachusetts Institute of Technology
Broad Institute of MIT and Harvard)
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet most patients fail to achieve durable responses. To better understand the tumor microenvironment (TME), we analyze single-cell RNA-seq (~189 K cells) from 36 metastatic melanoma samples, defining 14 cell types, 55 subtypes, and 15 transcriptional hallmarks of malignant cells. Correlations between cell subtype proportions reveal six distinct clusters, with a mature dendritic cell subtype enriched in immunoregulatory molecules (mregDC) linked to naive T and B cells. Importantly, mregDC abundance predicts progression-free survival (PFS) with ICIs and other therapies, especially when combined with the TCF7 + /– CD8 T cell ratio. Analysis of an independent cohort (n = 318) validates mregDC as a predictive biomarker for anti-CTLA-4 plus anti-PD-1 therapies. Further characterization of mregDCs versus conventional dendritic cells (cDC1/cDC2) highlights their unique transcriptional, epigenetic (single-nucleus ATAC-seq data for cDCs from 14 matched samples), and interaction profiles, offering new insights for improving immunotherapy response and guiding future combination treatments.
Suggested Citation
Jiekun Yang & Cassia Wang & Doris Fu & Li-Lun Ho & Kyriakitsa Galani & Lee Chen & Jose Gonzalez & Jolene Fu & Amy Y. Huang & Dennie T. Frederick & Liang He & Mukta Asnani & Rahul Tacke & Emily J. Robi, 2025.
"Mature and migratory dendritic cells promote immune infiltration and response to anti-PD-1 checkpoint blockade in metastatic melanoma,"
Nature Communications, Nature, vol. 16(1), pages 1-19, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62878-5
DOI: 10.1038/s41467-025-62878-5
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62878-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.